Viatris Inc (VTRS): what the price assumes

In the published model solve dated 2026-Q2, anchored at $17.64, Viatris Inc (VTRS) is priced for today's economics sustained for ~9.1 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-08-07.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/VTRS

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.7 years (computed at the 7% minimum rate; the CAPM rate 6.3% sits below it).

Reconcile: at the x-ray's 9.3% required return this reads ~14.7 years; the models below use their own rates.

How unusual the bet is: elevated

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 5.7%); the inversion above states its own rate.

Per-Model Detail (n=4)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 2.5%); the trailing year was depressed.

Bullet Takeaways

• Reported profit is mostly an accounting artifact: roughly 2.36 billion dollars of purchase-accounting amortisation ran through the income statement in the year to March 2026, which is why operating profit of 139.4 million dollars sits alongside guided 2026 operating cash generation of 1.9 to 2.1 billion dollars.
• The clearest near-term risk is supply rather than demand: the Nashik oral solid dose plant drew FDA Form 483 observations in May 2026 on top of a February fire, and the company expects 100 to 150 million dollars of revenue to be lost in the second half of 2026.
• Greater China is the one region genuinely growing, up 21% in the June 2026 quarter to 713.8 million dollars of sales, while Emerging Markets and JANZ both shrank.

Bull Case

Every standard way of valuing this company reaches a different answer, and for once the disagreement is the useful part. The book-value approaches set a floor the price sits roughly half again above. Capitalising the cash the business throws off today, crediting it no growth whatsoever and then deducting what it owes, lands far lower still. Only the methods that project cash flow forward reach the quoted price. That is the signature of a company whose reported earnings and whose actual cash generation have been pulled apart, and here the thing that pulled them apart is a single accounting entry.

Viatris was assembled out of Mylan and Upjohn. The purchase accounting that followed created an intangible asset base that has been amortising ever since. In the twelve months ended March 31, 2026 that charge came to roughly 2.36 billion dollars, set against operating profit of 139.4 million dollars. Amortising an intangible consumes nothing. It is the bookkeeping recognition of a cheque written years ago. Look instead at what the business collects, and a different company appears: management guides 2026 net cash provided by operating activities to 1.9 to 2.1 billion dollars.

Growth, where it exists, is concentrated in one place. The annual report records that Net sales from Greater China increased by $166.0 million, or 8%, for the year ended December 31, 2025 when compared to the prior year, and the June 2026 quarter accelerated that to 21% growth on sales of 713.8 million dollars. By product category, Brands is roughly 64% of the mix and grew 6% in the quarter; Generics grew 3%. Nobody should mistake that for a growth company. It is a company where one region and the branded half of the portfolio are doing the work while the rest holds level.

Capital allocation has been unusually legible for a business this complicated. In July, Viatris completed the sale of its Biocon equity position for roughly 380 million dollars of pre-tax consideration, finishing a monetisation worth about 780 million dollars in total, and the FDA approved Gwyn Lo, a low-dose combined hormonal contraceptive patch the company expects to sell later this year. The proceeds went two ways. Roughly 900 million dollars of June 2026 maturities were repaid and refinanced with 650 million euros of 4.250% notes due 2033, and about 270 million dollars of stock was repurchased through early August at a weighted average of 16.42 dollars a share. Share count has fallen about 0.8% a year since early 2022, which is a small number that has now compounded quietly for a while.

The bull case does not require a re-rating or a new drug. It requires the amortisation schedule to run off while the cash keeps arriving. Every year a slice of that 2.36 billion dollar annual charge expires, and reported operating profit rises without the business doing anything differently. On August 6 management raised the midpoint of every 2026 guidance measure it provides. In an industry where the default expectation is decline, standing still while the accounting normalises is most of the argument.

Bear Case

Generic pharmaceuticals is an industry where the price of nearly everything you sell falls every year, by design. The annual report does not dress it up: We operate in a challenging environment, with significant pressures on the pricing of our products. It names the mechanism too, describing how the emergence of large buying groups representing retail and wholesale pharmacies and the prevalence and influence of managed care organizations and similar institutions increases the negotiating power of these groups, enabling them to attempt to extract price discounts, rebates, and other restrictive pricing terms. That is a structural position on the cost curve, and it does not rotate with the cycle.

Set that against what the quoted price requires. In the twelve months ended March 31, 2026, sales of roughly 14.5 billion dollars produced operating profit of 139.4 million dollars, a margin near 1%; the company's own through-the-cycle margin is about 2.5%. The price asks for operating profit to compound at the ceiling the business can fund from its own earnings and to stay there for about 9 years. Of companies that have grown that fast, only around 19% kept it going that long. The company's own accountants assume nothing of the kind: in the impairment test performed as of March 31, 2025, management forecast that the revenue compound annual growth rate was approximately 3.3 % and that A terminal year value was calculated with a 2.0 % revenue growth rate applied. That test wrote off about 2.9 billion dollars of goodwill.

The nearer worry is whether the company can make what it sells. A fire suspended production at the Nashik oral solid dose facility in India in February; in May the FDA inspected the same plant and issued Form 483 observations. Production has restarted, the disruptions are intermittent, and the company now expects 100 to 150 million dollars of revenue to be lost in the second half of 2026. The annual report treats this class of event as ordinary rather than exceptional, noting that we or our partners have in the past and may in the future receive notices of manufacturing and quality-related observations following inspections by regulatory authorities around the world. When your product is interchangeable by definition, a supply gap is not a deferred sale. It is a customer who bought elsewhere.

Two of four regions are already shrinking. Emerging Markets fell 2% in the June quarter and JANZ fell 3%. The annual report explains part of it directly: In many emerging markets, we face increased competition and contracting markets for certain of our ARV products, primarily related to competing therapies. Behind all of it sits the debt the merger built. Borrowings stood near 14.3 billion dollars on March 31, 2026 against cash of about 1.8 billion, and the trailing interest bill of roughly 476 million dollars ran well ahead of the 139.4 million dollars of operating profit reported for the same span. Lenders are being paid out of cash flow, not out of reported earnings.

None of this makes the company fragile. It makes the equity a claim on a slowly eroding revenue stream with a large fixed obligation standing in front of it. The bull needs the amortisation to roll off faster than the pricing erodes. The bear needs only the reverse, and in this industry the reverse is the ordinary outcome rather than the bad one.

Valuation

There is a useful benchmark buried in the FY2025 annual report. When Viatris tested its goodwill for impairment as of March 31, 2025, management had to write down what it genuinely expected the business to do. It forecast that the revenue compound annual growth rate was approximately 3.3 % over the following decade, with A terminal year value was calculated with a 2.0 % revenue growth rate applied and The discount rate utilized was 12.0 %. That exercise produced a write-off of about 2.9 billion dollars. Hold it in mind, because the quoted price implies something considerably more ambitious.

Reported earnings are too small to build a multiple on, so the read here uses the company's own through-the-cycle margins on current revenue rather than the trough year. On that basis the market pays roughly 96 dollars for each dollar of normalised operating profit, which inverts into operating profit compounding at the fastest rate the business can self-fund and holding there for about 9 years. Treat that as a shape rather than a measurement: the horizon is highly sensitive to the growth rate assumed, and a single percentage point moves it by years.

How far past the evidence does that sit? Only about 19% of comparable fast-growers sustained such a pace across a stretch of that length, and that base rate is what marks the assumption as an elevated one. The company's recent pace, by contrast, is within what it has actually delivered; the stretch is in how long it must persist, not in the rate itself. The methods then split cleanly. The price stands about half again above the floor the book-value approaches set. Capitalising today's free cash flow with no growth credited, then deducting what the company owes, leaves considerably less than that. The forward-projection methods are the sole approach that gets there, and they arrive by carrying the current cash generation base outward and holding an exit multiple flat. The price is defended by the methods that credit the future and by none that measure the present.

The peer picture explains the reported margin better than any competitive story does. BHC converted 10.9 billion dollars of trailing revenue into an 8.1% operating margin; AMRX ran 14.3% on 3.0 billion dollars of revenue; OGN, closest in shape and portfolio, shrank revenue 2.5% over its trailing year. Viatris's reported margin near 1% sits under all of them, and the reason is not competitiveness. It is that roughly 2.36 billion dollars of intangible amortisation passes through the line above it.

Which leaves the balance sheet as the binding constraint. Borrowings near 14.3 billion dollars on March 31, 2026 against cash of about 1.8 billion, and a trailing interest bill around 476 million dollars set against operating profit of 139.4 million dollars. Interest coverage reaches roughly 0.8 only when measured on through-the-cycle profit; on what was actually reported it does not reach 1 at all, and the difference is made up by cash the income statement never shows. By the June quarter borrowings had been cut further and the company reported its own gross leverage measure down to 2.9. The direction of travel is right. What the price assumes is that the direction holds for the better part of a decade.

Catalysts

The June 2026 quarter, reported on August 6, was better than the headline suggested. Total net sales rose 5% to 3,745.9 million dollars, with Greater China up 21% to 713.8 million and Developed Markets up 4% to 2,193.7 million, while Emerging Markets fell 2% and JANZ fell 3%. Gross margin on a reported basis improved to 38.8% from 37.2%. The GAAP net loss of 118.8 million dollars was driven almost entirely by a non-cash charge of 177.8 million dollars taken on the planned sale of the Tyrvaya product rights. Management raised the midpoint of every 2026 guidance measure it publishes, and now expects total revenues of 14,550 to 14,950 million dollars for the year.

Portfolio activity has been steady in both directions. In August the company signed a definitive agreement to sell global rights to Tyrvaya to Harrow for 30 million dollars upfront plus 70 million dollars of contingent commercial milestones. In July the FDA approved Gwyn Lo and Viatris completed the sale of its Biocon equity stake for roughly 380 million dollars pre-tax. In June the FDA approved the company's generic ferric carboxymaltose injection in three strengths, and a Phase 3 trial of VR-205 in Japanese patients with primary IgA nephropathy read out positive on its top-line endpoints.

Two dates matter from here. The FDA has set a PDUFA goal date of December 27, 2026 for MR-107A-02, a fast-acting non-opioid meloxicam for moderate-to-severe acute pain, which is the largest single approval decision in front of the company. Before that, the second half carries an expected 100 to 150 million dollar revenue hit from the Nashik supply disruptions, against a full-year new product revenue expectation of 450 to 550 million dollars. The first tells you whether the pipeline is worth anything. The second tells you whether the base business can be relied on to deliver what it has already sold.

Peer Cohorts (Per Segment, With Filing Citations)

Developed Markets / JANZ / Emerging Markets (reported)

• TEVA (TEVA PHARMACEUTICAL INDUSTRIES LIMITED)
• FY2025 10-K: …due to inflationary pressure in certain markets and a favorable mix of products. International Markets R&D Expenses R&D expenses relating to our International Markets segment in 2025 were $103 million, a decrease of 8% compared to $112 million in 2024. For a description of our R&D expenses in 2025, see "-Teva…
• FY2025 10-K: …in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The majority of the Group's revenues are in the United States and Europe. Basis of presentation and use of estimates The consolidated financial statements are prepared in accordance with accounting…
• OGN (Organon & Co.)
• FY2025 10-K: …Director Savings Plan, as amended and restated on January 1, 2025 (incorporated herein by reference to Exhibit 10.15 to the Company's Form 10-K filed on February 28, 2025) ♦+10.17 - Development and Commercialization Agreement, dated February 18, 2013, by and between Samsung Bioepis Co., Ltd. and Merck Sharp & Dohme…
• FY2025 10-K: …2025-12-31 0001821825 ogn:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001821825 ogn:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0001821825 ogn:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2024-12-31…
• AMRX (AMNEAL PHARMACEUTICALS, INC.)
• FY2025 10-K: …amrx:ResearchAndDevelopmentReimbursementMember 2020-08-01 2020-08-31 0001723128 srt:AffiliatedEntityMember amrx:KashivBioSciencesLLCMember amrx:GanirelixAcetateAndCetrorelixAcetateMember amrx:DevelopmentMilestonesMember amrx:ResearchAndDevelopmentReimbursementMember 2020-08-01 2020-08-31 0001723128…
• FY2025 10-K: RestatementAdjustmentMember 2023-01-01 2023-12-31 0001723128 amrx:CustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-12-31 0001723128 amrx:CustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2024-01-01…
• PRGO (Perrigo Company plc)
• FY2025 10-K: …from input costs that are denominated in a currency other than the local reporting currency and 2) the revaluation of transaction-related working capital balances denominated in currencies other than the functional currency. Significant exchange rate fluctuations, especially in the Euro or the British Pound Sterling,…
• FY2025 10-K: …swap agreements Other non-current assets 1.1 9.3 Total designated derivative assets $ 1.4 $ 25.6 Non-designated derivative assets: Foreign currency forward contracts Prepaid expenses and other current assets $ 2.1 $ 3.4 Total non-designated derivatives $ 2.1 $ 3.4 Designated derivative liabilities: Foreign currency…
• BHC (Bausch Health Companies Inc.)
• FY2025 10-K: :PensionPlansDefinedBenefitMember bhc:EmergingMarketsMember 2024-12-31 0000885590 us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember us-gaap:FairValueInputsLevel1Member bhc:NonU.S.DevelopedMarketsMember 2025-12-31 0000885590…
• FY2025 10-K: …us-gaap:PensionPlansDefinedBenefitMember country:US us-gaap:FairValueInputsLevel3Member bhc:U.S.BroadMarketMember 2024-12-31 0000885590 country:US us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember bhc:U.S.BroadMarketMember 2024-12-31 0000885590…
• PFE (Pfizer Inc.)
• FY2025 10-K: …alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs. Equity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in the…
• FY2025 10-K: …srt:PartnershipInterestMember 2024-12-31 0000078003 country:US us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember srt:PartnershipInterestMember 2024-12-31 0000078003 country:US us-gaap:PensionPlansDefinedBenefitMember pfe:InsuranceContractsMember 2025-12-31 0000078003…
• ABBV (AbbVie Inc.)
• FY2025 10-K: …in both developed and emerging markets. (d) Securities held by actively managed accounts, index funds and mutual funds. (e) Primarily funds having global mandates with the flexibility to allocate capital broadly across a wide range of asset classes and strategies, including but not limited to equities, fixed income,…
• FY2025 10-K: …us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2024-01-01 2024-12-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-01-01 2023-12-31…
• BMY (Bristol-Myers Squibb Company)
• FY2025 10-K: CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2024-12-31 0000014272 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:LiabilityMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2024-12-31 0000014272…
• FY2025 10-K: …0000014272 2025 FY FALSE P3Y0M0D http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.